NewAmsterdam Pharma Company N.V.

US$18.90As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NAMSHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 11.41%
Div yield —
ROE (30.16%)
Biotechnology
Beta (5Y) 0.14
PE TTM —
TSR TTM (50.20%)
Mkt cap US$2.267B
ROIC (21.47%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$22
17.58%
137.20%
Hold 6|8|1|3|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.19
0.20
0.22
0.22
7.41%
9.25%
18.33%
23.20%
Revenue$M
110.0
115.3
121.8
124.3
11.63%
14.57%
20.39%
16.48%
Peers (US$2.267B)
Cap (US$)
PE
1.522B
—
875.4M
43.62x
2.280B
—
Capital
TTM
5Y
10Y
Leveragex
3.168
(0.195)
(0.182)
EBIT/Intx
1.703
0.035
0.039
Own earn%
(40.89)
(28.53)
(36.52)
Sh yield%
47.84
53.34
52.38
Owners
Insiders/Inst%
8.16
67.19
Short interest%
5.19
SBC / revenue%
5.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
7–15
$1 testx
—
Incr. ROIC%
4